Literature DB >> 33551444

The Predictive Values of Different Small Vessel Disease Scores on Clinical Outcomes in Mild ICH Patients.

Tianqi Xu1, Yulan Feng2, Weiwen Wu3, Fanxia Shen1,4, Xiaodong Ma5, Weiping Deng4, Bei Zhang6, Jin Hu7, Yi Fu1.   

Abstract

AIM: To explore the predictive values of different small vessel disease (SVD) scores on functional recoveries and the clinical cerebrovascular events in mild intracerebral hemorrhage (ICH).
METHODS: In this study, we enrolled conscious and mild ICH patients without surgery and further divided them into the cerebral amyloid angiopathy (CAA)-ICH group and hypertension (HTN)-ICH group. The severity of individual SVD markers, including lacunes, cerebral microbleeds (CMBs), enlarged perivascular spaces (EPVS), white matter hyperintensity (WMH), and cortical superficial siderosis (cSS), was evaluated. The original SVD score, modified SVD score, refined SVD score, and CAA-SVD score and the total number of SVD markers were further calculated. Functional recoveries were evaluated using the modified Rankin scale. Recurrences of stroke were defined as readmission to the hospital with a definite diagnosis of stroke.
RESULTS: A total of 163 ICH patients (60 CAA-ICH and 103 HTN-ICH) were included in the study. The CAA-SVD score (OR=3.429; 95% confidence interval (CI)=1.518-7.748) had the best predictive effect on functional dependence in the CAA-ICH group, among which cSS severities probably played a vital role (OR=4.665; 95% CI=1.388-15.679). The total number of SVD markers [hazard ratio (HR)=3.765; 95% CI=1.467-9.663] can better identify stroke recurrences in CAA-ICH. In HTN-ICH, while the total number of SVD markers (HR=2.136; 95% CI=1.218-3.745) also demonstrated association with recurrent stroke, this effect seems to be related with the influence of lacunes (HR=5.064; 95% CI=1.697-15.116).
CONCLUSIONS: The CAA-SVD score and the total number of SVD markers might identify mild CAA-ICH patients with poor prognosis. However, it would be better to focus on lacunes rather than on the overall burden of SVD to predict recurrent strokes in HTN-ICH.

Entities:  

Keywords:  CAA-related ICH; Clinical cerebrovascular events; Different Small Vessel Disease Scores; Functional recoveries; HTN-related ICH

Mesh:

Year:  2021        PMID: 33551444      PMCID: PMC8532058          DOI: 10.5551/jat.61267

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


Introduction

Cerebral small vessel disease (CSVD) is a disorder of the penetrating cerebral small vessels, such as arterioles, capillaries, and venules [1)] . Lacunas, cerebral microbleeds (CMBs), enlarged perivascular spaces (EPVS), white matter hyperintensities (WMH), and cortical superficial siderosis (cSS) are all imaging markers of CSVD [2 - 6)] . Previous studies have demonstrated the clinical significance of individual and separated CSVD markers on cognitive impairments, functional recoveries, and stroke recurrences in patients with stroke [7 - 9)] . However, different CSVD markers could be simultaneously presented in one patient, and recent studies have attempted to convey more information by conducting different semi-quantitative assessments of the cumulative burden. The concept of the original SVD score [10 , 11)] and the modified SVD score [12)] , evaluated by lacunas, CMBs, EPVS, and WMHs, was first introduced in ischemic stroke patients. Moreover, it has been pointed out that the original SVD score significantly influenced the functional recoveries of ICH patients [13)] . Other scholars believed that the total number of the four SVD markers previously mentioned could also predict the adverse functional outcome of ICH [14)] . Besides, to accurately calculate the total SVD burden in cerebral amyloid angiopathy (CAA) patients, the cerebral amyloid angiopathy-small vessel disease (CAA-SVD) score evaluating lobar CMBs, centrum semiovale (CSO)-EPVS, WMH, and cSS was further proposed to demonstrate the underlying pathological severity of CAA [15)] . Subsequently, researchers found that the CAA-SVD score could be adapted to predict the risk of ICH recurrence in patients with CAA [16)] . In this study, for the first time, we put those five individual markers together and summarized the effect of different SVD scores on the prognosis of ICH patients with different etiologies. Furthermore, as deep CMBs and hypertensive ICH may be closely related [17)] , we proposed the refined SVD score in the HTN-ICH group by placing more emphasis on deep CMBs, especially severe deep CMBs. In our years of clinical practice, we have found that clinicians usually focus more on comatose ICH patients requiring surgical treatments due to the high rates of mortality and disability. However, for mild and conscious ICH patients supported with conservative medication, neurologists may be less proactive in the follow-up due to the relatively good prognosis. Thus, we enrolled mild spontaneous ICH patients without surgical treatment and further divided them into the CAA-ICH or HTN-ICH groups. We would like to explore the following questions: (1) among mild ICH patients with different etiologies, whether individualized and calculated burden of SVD markers could predict functional dependence and stroke recurrence, and (2) in different semi-quantitative methods of the SVD burden, whether there is a difference in the predictive ability of prognosis. The analysis might help neurologists identify mild ICH patients with poor outcomes and take effective preventive measures in advance.

Methods

Patients

This study retrospectively analyzed prospectively collected data from an observational study of conscious and spontaneous ICH patients without surgery. Patients were recruited from August 2012 to October 2019 in the neurology wards in seven independent general hospitals with stroke units accredited by the Chinese Stroke Association. These seven hospitals were Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Ruijin North Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Pudong District Gongli Hospital, Jiaxing First Municipal Hospital, Zhongshan Hospital Qingpu Branch affiliated to Fudan University, Minhang Hospital affiliated to Fudan University, and Haiyan County People’s Hospital. According to the modified Boston criteria, the inclusion criteria for CAA-ICH patients were as follows: 1) age ≥ 55 years; 2) multiple hemorrhages restricted to the lobar, cortical, or corticosubcortical regions (cerebellar hemorrhage allowed) or single lobar, cortical, or corticosubcortical hemorrhage and focal or disseminated superficial siderosis; and 3) the absence of other causes of hemorrhage [18 , 19)] . The inclusion criteria for the HTN-ICH patients were as follows: 1) ≥ 1 year of hypertension history; 2) hemorrhages (ICH and CMBs) restricted to the deep regions with or without deep microbleeds but no lobar microbleeds [20)] . The exclusion criteria were as follows: 1) ICH secondary to brain tumors, trauma, or hematological diseases; 2) mixed hemorrhage (ICH and CMBs) in the lobar and deep regions; 3) deep hematomas without hypertension; 4) lobar, cortical, or subcortical hematomas with age <55 years; 5) examination with computed tomography (CT) scan over 3 days or magnetic resonance imaging (MRI) over 7 days following onset; 6) without completed or qualified clinical and imaging data; 7) lost to follow-up; and 8) pregnancy or refusal to participate in the study. This study was approved by the ethics committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Written informed consent for data collection and clinical outcomes was obtained from the patient or a legally authorized representative in all cases.

Imaging Analysis

All patients were examined via cranial CT within 3 days and MRI within 7 days following ICH onset. A GE Signa HDxT 3.0 T superconducting MRI system was utilized. All patients were first examined with axial T1WI, T2WI, and then diffusion-weighted imaging and susceptibility-weighted imaging (SWI). In this multicenter study, different hospitals used the same imaging parameters. All imaging data were randomly read and recorded by two senior radiologists under double-blind conditions. The inter-rater reliability of neuroimaging variable was tested using the kappa statistic. Neuroimaging markers for CSVD were evaluated according to the STandards for Reporting Vascular changes on nEuroimaging (STRIVE criteria) [21)] . Lacunes were defined as rounded or ovoid lesions of cerebrospinal fluid signal, that is, hyperintensities on a T2-weighted sequence with corresponding hypointensities with a hyperintense rim on fluid-attenuated inversion recovery (FLAIR), ranging from 3 to 20 mm in diameter in bilateral hemispheres [22)] . CMBs were defined as round or oval foci with a low signal or signal loss on SWI, generally with diameters ranging from 2 to 5 mm and a maximum of 10 mm. CMB severity was classified as mild ( n =1), moderate ( n =2–4), or severe ( n ≥ 5) [23)] . EPVS were defined as <3 mm punctate or linear hyperintensities on a T2-weighted sequence with corresponding hypointensities on a T1/FLAIR sequence. EPVS were rated in the regions of the centrum semiovale (CSO) and basal ganglia (BG). EPVS severity was classified as mild (≤ 10 EPVS), moderate (11–20 EPVS), or severe (≥ 20 EPVS) [24)] . WMHs were identified as white matter hyperintensities on the FLAIR sequence. WMHs in the deep (DWMH) and periventricular (PVWMH) regions were graded from 0 to 3 using the semi-quantitative Fazekas scale. WMH severity was classified as mild (Fazekas score=1–2), moderate (Fazekas score=3–4), or severe (Fazekas score=5–6) [24)] . cSS was defined as curvilinear signal loss on gradient-recalled echo following the cortical gyral surface, and cSS severity was classified as focal (≤ 3 sulci) or disseminated (>3 sulci) [27)] . In this study, only one patient had acute convexity subarachnoid hemorrhage (cSAH), lacking statistical value. Thus, these data were not reflected in the paper. The original SVD score (0–4) [10)] was assessed as follows: presence of lacunes, 1 point; presence of CMBs, 1 point; >10 BG-EPVS, 1 point; and periventricular WMH (Fazekas=3) or deep WMH (Fazekas=2–3), 1 point. The modified SVD score (0–6) [12)] was assessed as follows: presence of lacunes, 1 point; 1–4 CMBs, 1 point; ≥ 5 CMBs, 2 points; >20 BG-EPVS, 1 point; moderate WMH (total Fazekas=3–4), 1 point; and severe WMH (total Fazekas=5–6), 2 points. The CAA-SVD score (0–6) [28)] was assessed as follows: 2–4 lobar CMBs, 1 point; ≥ 5 lobar CMBs, 2 points; >20 CSO-EPVS, 1 point; confluent deep WMHs (Fazekas score=2 or 3) or irregular periventricular WMHs extending into the deep white matter (Fazekas score=3): 1 point focal; cSS, 1 point; and disseminated cSS, 2 points. Since patients with deep CMBs were excluded from the CAA-ICH group and those with lobar CMBs were excluded from the HTN-ICH group, we proposed the refined SVD score in HTN-ICH patients by placing more emphasis on deep CMBs, especially severe deep CMBs: presence of lacunes, 1 point; 2–4 deep CMBs, 1 point, ≥ 5 deep CMBs, 2 points; >20 BG-EPVS, 1 point; moderate WMH (total Fazekas=3–4), 1 point; and severe WMH (total Fazekas=5–6), 2 points. The total number of SVD markers was assessed as follows: 1 point for each of the presence of lacunes, CMBs, EPVS, WMHs, and cSS ( . Features and categories of different small vessel disease scores

Prognoses

Within 1 year after the onset, patients were followed up via telephone every 3 months by trained professional neurologists. We used two prognostic end points: functional dependence and stroke recurrence. Functional dependence was measured 3 months after the onset and was defined as modified Rankin scale (mRS) >2 [29)] . Recurrent stroke was defined as a sudden new neurologic deficit that suits the definition of ischemic stroke or ICH. Patients with suspected recurrent stroke received repeat neuroimaging in the form of cranial CT or MRI to support the diagnosis.

Statistical Methods

We consulted professional statisticians to conduct the statistical analysis. The SPSS 22.0 software (SPSS Inc., Chicago, IL, USA) and the GraphPad Prism 8.0 software (GraphPad, San Diego, CA, USA) were utilized. ICH patients were divided into the CAA-ICH group and HTN-ICH group. The baseline clinical data and imaging data of these two groups were then compared. Continuous variables were analyzed using the Kolmogorov–Smirnov normal test. The data following a normal distribution were expressed as mean±standard deviation, and a t test was employed. For non-normal continuous variables, data were expressed as medians (interquartile ranges), and the Mann–Whitney U test was employed. Categorical variables were expressed as frequencies or percentages and analyzed using either the χ 2 test or Fisher’s exact test. Univariable logistic regression was employed with functional dependence as dependent variable and different SVD scores as independent variables. Backward stepwise multiple logistic regression analysis was then conducted. Age, sex, and baseline clinical characteristics associated with functional dependence in the univariable analysis ( P <0.1) were further used as covariates. Univariable Cox regression was employed to analyze the relationship between stroke recurrence and different SVD scores. Backward stepwise multiple Cox regression analysis was conducted, with age, sex, and vascular risk factors fully adjusted.

Data Availability Statement

Patient-related data will be shared upon request by the corresponding author or any qualified investigator.

Results

Study Population

A total of 163 patients (60 with CAA-ICH and 103 with HTN-ICH) were finally included in the study ( . Three patients died during the 1-year follow-up: two died of recurrent stroke, whereas the other one died of heart disease. Compared with HTN-ICH patients, CAA-ICH patients were more likely to be older and have larger hematoma volumes but milder clinical symptoms upon admission, as assessed by the National Institutes of Health Stroke Scale (NIHSS) score. In addition, CAA-ICH patients ( P <0.05 for all) were found to have more SVD markers (cSS, severe CSO-EPVS, and severe WMH) and higher CAA-SVD score. Baseline clinical characteristics and radiological outcomes are presented in .
Table 1.

Baseline Characteristics of the Study Population

Total Cohort ( N = 163) CAA-related ICH ( n = 60) HTN-related ICH ( n = 103) P value
Baseline clinical characteristics
Age, means±SD63.3±13.671.0±9.958.8±11.8<0.001
Sex, male (%)100 (61.3)32 (53.2)68 (66.0)0.109
Hypertension, n (%) 132 (80.9)29 (48.3)103 (100)<0.001
Diabetes mellitus, n (%) 27 (16.6)10 (16.7)17 (16.5)0.542
Dyslipidemia, n (%) 38 (23.3)15 (25.0)23 (22.3)0.698
Atrial fibrillation, n (%) 6 (3.9)4 (6.7)2 (1.9)0.194
Previous stroke, n (%) 23 (14.1)13 (21.7)10 (9.7)0.034
Antiplatelet use , n (%) 27 (16.6)12 (20.0)15 (14.6)0.300
Statin use, n (%) 15 (9.2)7 (11.7)8 (7.8)0.209
Admission NIHSS, median (IQR)4 (2-6)2 (1-5)4 (2-7)0.001
Admission GCS, median (IQR)15 (15-15)15 (15-15)15 (15-15)0.319
Hematoma volume, means±SD9.4±10.412.4±13.27.6±7.90.004
Imaging characteristics
Lacunes, n (%) 26 (16.0)7 (11.7)19 (18.4)0.254
CMBs, n (%) 65 (39.9)22 (36.2)43 (41.7)0.523
128 (17.2)13 (21.7)15 (14.6)0.246
2~428 (17.2)7 (11.7)21 (20.4)0.155
≥ 59 (5.5)2 (3.3)7 (6.8)0.488
lobar16 (9.8)16 (26.7)0 (0)<0.001
deep39 (23.9)0 (0)39 (37.9)<0.001
> 20 CSO-EPVS, n (%) 34 (20.8)23 (38.3)11 (10.7)<0.001
> 20 BG-EPVS, n (%) 18 (11.0)5 (8.3)13 (12.6)0.400
WMHs, n (%) 122 (74.8)46 (76.7)76 (73.8)0.683
1-237 (22.7)8 (13.3)29 (28.2)0.029
3-448 (29.4)18 (30.0)30 (29.1)0.906
5-637 (22.7)20 (33.3)17 (16.5)0.013
cSS, n (%) 11 (6.7)9 (15.0)2 (1.9)0.002
Disseminated cSS7 (4.3)6 (10.0)1 (1.0)0.006
Focal cSS4 (2.5)3 (5.0)1 (1.0)0.109
The original SVD score, median (IQR)1 (0-2)1 (1-2)1 (0-2)0.570
The modified SVD score, median (IQR)1 (1-3)1 (1-3)1 (0-2)0.567
The refined SVD score, median (IQR)1 (0-2)1 (0-2)1 (0-2)0.822
The CAA-SVD score, median (IQR)1 (0-1)1 (0-2)0 (0-1)<0.001
Total number of SVD markers, median (IQR)1 (1-2)1 (1-2)1 (1-2)0.779
Recurrent stroke21 (12.9)8 (13.3)13 (12.6)0.975

Abbreviation: HTN = Hypertension; CAA = Cerebral amyloid angiopathy; ICH = Intracerebral Hemorrhage; NIHSS = National Institutes of Health Stroke Scale; GCS = Glasgow Coma Scale; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMHs = White Matter Hyperintensities; EPVS = Enlarged Perivascular Spaces; CSO = Centrum Semiovale ; BG = Basal Ganglia; SVD = Small Vessel Disease; Results are expressed as numbers (column %), means (SD) or medians (interquartile range) as appropriate.

Study flowchart Abbreviation: HTN = Hypertension; CAA = Cerebral amyloid angiopathy; ICH = Intracerebral Hemorrhage; NIHSS = National Institutes of Health Stroke Scale; GCS = Glasgow Coma Scale; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMHs = White Matter Hyperintensities; EPVS = Enlarged Perivascular Spaces; CSO = Centrum Semiovale ; BG = Basal Ganglia; SVD = Small Vessel Disease; Results are expressed as numbers (column %), means (SD) or medians (interquartile range) as appropriate.

Univariate Analysis of Factors Associated with Functional Dependence

In the CAA-ICH group, 11 patients (18.3%) were found to be functionally dependent 3 months after onset. Univariable analyses revealed that cSS (OR=4.322; 95% CI=1.624–11.503; P =0.003) and the CAA-SVD score (OR=3.299; 95% CI=1.656–6.572; P =0.001) demonstrated stronger associations with functional dependence compared with other individual and total burden of SVD markers. In the HTN-ICH group, 19 patients (18.4%) were found to exhibit functional dependence. The modified SVD score (OR=1.764; 95% CI=1.151–2.704; P =0.009) and the refined SVD score (OR=1.893; 95% CI=1.202–2.980; P =0.006) both demonstrated correlations with functional dependence in the univariable analyses ( . Abbreviation: HTN = Hypertension; CAA = Cerebral amyloid angiopathy; ICH = Intracerebral Hemorrhage; NIHSS = National Institutes of Health Stroke Scale; GCS = Glasgow Coma Scale; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMHs = White Matter Hyperintensities; EPVSs = Enlarged Perivascular Spaces; CSO = Centrum Semiovale ; BG = Basal Ganglia; SVD = Small Vessel Disease. * Functional dependence was measured 3 months after onset and defined as the modified Rankin scale (mRS) > 2

Univariate Analysis of Factors Associated with Stroke Recurrence

In the CAA-ICH group, eight patients (13.3%) have suffered recurrent stroke within 1 year of ICH onset, including three cases of ischemic stroke and five cases of hemorrhagic stroke. The total number of SVD markers (OR=3.839; 95% CI=1.505–9.794; P =0.005) demonstrated the highest hazard ratio (HR) in univariable analyses among different SVD scores. In the HTN-ICH group, 13 patients (12.6%) had suffered recurrent stroke, including 10 cases of ischemic stroke and three cases of hemorrhagic stroke. Univariable analyses revealed that stroke recurrence was associated with the original SVD score, modified SVD score, refined SVD score, and total number of SVD markers. However, those correlations may be significantly related to the influence of lacunes (OR=6.132; 95% CI=2.054–18.311; P =0.001) ( . Abbreviation: HTN = Hypertension; CAA = Cerebral Amyloid Angiopathy; ICH = Intracerebral Hemorrhage; NIHSS = National Institutes of Health Stroke Scale; GCS = Glasgow Coma Scale; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMHs = White Matter Hyperintensities; EPVSs = Enlarged Perivascular Spaces; CSO = Centrum Semiovale ; BG = Basal Ganglia; SVD = Small Vessel Disease.

Multiple Logistic Regression Analysis Between Functional Dependence and Different SVD Scores

After conducting univariate analyses to determine the factors associated with poor functional outcomes, age, sex, and variables with a P <0.10 in were used in the multivariate logistic regression as covariates. The multivariate analyses revealed that the CAA-SVD score (OR=3.429; 95% CI=1.518–7.748; P =0.003) was probably better to predict functional dependence in the CAA-ICH group ( . Conversely, in the HTN-ICH group, the admission NIHSS (OR=1.556; 95%CI=1.262-1.918; P <0.001) may have a stronger effect on functional dependence compared with individuals and total burden of CSVD markers ( .
Table 2.

Univariate analysis of factors associated with functional dependence *

CAA-related ICH ( n = 60) HTN-related ICH ( n = 103)
OR (95% CI) P value OR (95% CI) P value
Baseline clinical characteristics
Age1.082 (1.007-1.162)0.0311.031 (0.987-1.076)0.176
Male0.942 (0.253-3.501)0.9290.875 (0.301-2.544)0.807
Hypertension0.737 (0.198-2.740)0.649//
Diabetes mellitus1.111 (0.201-6.143)0.9040.541 (0.113-2.596)0.443
Dyslipidemia1.025 (0.365-6.348)0.5631.126 (0.438-7.462)0.413
Previous stroke0.768 (0.144-4.089)0.7571.118 (0.218-5.740)0.894
Antiplatelet use1.061 (0.222-5.078)0.9411.023 (0.136-3.046)0.867
Statin use0.702 (0.114-4.338)0.7030.921 (0.256-5.471)0.643
Admission NIHSS1.167 (0.984-1.384)0.0761.384 (1.187-1.614)<0.001
Admission GCS1.825 (0.303-10.979)0.5110.426 (0.209-0.869)0.019
Hematoma volume1.052 (1.000-1.108)0.0511.057 (0.998-1.120)0.059
Imaging markers of CSVD
Lacunes2.057 (0.330-12.809)0.4391.370 (0.425-4.419)0.598
CMBs1.126 (0.855-1.482)0.3991.190 (973-1.4554)0.090
EPVS2.763 (0.712-10.725)0.1421.818 (0.651-5.075)0.254
WMH1.458 (1.007-2.111)0.0461.215 (0.955-1.545)0.113
cSS4.322 (1.624-11.503)0.0032.822 (0.697-11.429)0.146
The original SVD score2.361 (1.033-5.398)0.0421.378 (0.854-2.223)0.189
The modified SVD score2.249 (1.203-4.208)0.0111.764 (1.151-2.704)0.009
The refined SVD score//1.893 (1.202-2.980)0.006
The CAA-SVD score3.299 (1.656-6.572)0.001//
Total number of SVD markers3.728 (1.502-9.252)0.0051.424 (0.800-2.538)0.230

Abbreviation: HTN = Hypertension; CAA = Cerebral amyloid angiopathy; ICH = Intracerebral Hemorrhage; NIHSS = National Institutes of Health Stroke Scale; GCS = Glasgow Coma Scale; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMHs = White Matter Hyperintensities; EPVSs = Enlarged Perivascular Spaces; CSO = Centrum Semiovale ; BG = Basal Ganglia; SVD = Small Vessel Disease.

* Functional dependence was measured 3 months after onset and defined as the modified Rankin scale (mRS) > 2

Abbreviation: SVD = Small Vessel Disease; CAA = Cerebral amyloid angiopathy; NIHSS = National Institutes of Health Stroke Scale; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMH = White Matter Hyperintensities; EPVS = Enlarged Perivascular Spaces; CSO = Centrum Semiovale. * Functional dependence was measured 3 months after onset and defined as the modified Rankin scale (mRS) >2 Abbreviation: SVD = Small Vessel Disease; HTN = Hypertension; NIHSS = National Institutes of Health Stroke Scale; GCS = Glasgow Coma Scale; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMH = White Matter Hyperintensities; EPVS = Enlarged Perivascular Spaces; BG = Basal Ganglia. * Functional dependence was measured 3 months after onset and defined as the modified Rankin scale (mRS) >2

Multiple Cox Regression Analysis Between Stroke Recurrence and Different SVD Scores

The multivariate analyses revealed that the total number of SVD markers (HR=3.765; 95% CI=1.467–9.663; P =0.006) might had the best predictive value for stroke recurrence in the CAA-ICH group ( . In the HTN-ICH group, while the total number of SVD markers (HR=2.136; 95% CI=1.218–3.745; P =0.008) also demonstrated association with recurrent stroke, this effect seems to be related with the influence of lacunes (HR=5.064; 95% CI=1.697–15.116; P =0.004) ( . Abbreviation: SVD = Small Vessel Disease; CAA = Cerebral amyloid angiopathy; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMH = White Matter Hyperintensities; EPVS = Enlarged Perivascular Spaces; CSO = Centrum Semiovale. Abbreviation: SVD = Small Vessel Disease; HTN = Hypertension; NIHSS = National Institutes of Health Stroke Scale; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMH = White Matter Hyperintensities; EPVS = Enlarged Perivascular Spaces; BG = Basal Ganglia.

Discussion

In this study, we attempted to determine whether different SVD scores have varying predictive effects on the prognosis of mild ICH patients. The results are summarized as follows: (1) The CAA-SVD score may be the best to predict poor functional outcome in CAA-ICH patients. (2) None of the SVD scores demonstrated association with functional dependence in the HTN-ICH group, which was somewhat unexpected. (3) Moreover, the total number of SVD markers was probably better than the CAA-ICH score to identify mild CAA-ICH patients with a high risk of recurrent stroke. (4) In the HTN-ICH group, while the total number of SVD markers was found to be significant for the prediction of recurrent stroke, this effect appeared to be related with the influence of lacunes. For the first time, we summarized the effect of different SVD scores on the prognosis of mild ICH patients without surgical treatment. Clinicians may be more concerned with the recoveries of severe ICH patients requiring surgery. Thus, our research may help neurologists identify mild ICH patients with poor prognosis and adopt effective preventive measures in advance. In this study, we found that the CAA-SVD score may be better to predict poor functional recoveries in mild CAA-ICH patients, whereas the total number of SVD markers may be more accurate to identify stroke recurrence in the same cohort. The CAA-SVD score was proposed by the introduction of cSS, which is an emerging SVD marker. There was a hypothesis holding that cSS could reflect repeated hemorrhage in the subarachnoid space from the superficial cortical vessels. Thus, cSS may be a marker of small-vessel fragility [30 , 31)] . Previous study has indicated that cSS is a stronger risk factor for ICH recurrence in CAA patients compared with the total CAA-SVD score [16)] . We failed to obtain a similar conclusion. However, our study indicated that the total number of SVD markers, rather than the specific disease phenotype, could better identify mild CAA-ICH patients with a high risk of stroke recurrence. This result may suggest the potential of cSS combined with other SVD markers to predict recurrent stroke in mild ICH patients. Furthermore, we innovatively found that the CAA-SVD score was also associated with functional dependence. These findings added to our understanding of the CAA neuroimaging profiles and their relationship with the clinical outcomes. More cases and longer follow-up durations would be required for further verifications. The limited association between the calculative burden of SVD markers and worse functional outcome in HTN-ICH patients was somewhat unexpected. Prior literature demonstrated that deep CMBs were related to HTN-ICH . Therefore, our expectation was that the refined SVD score would have a more profound effect. This result suggests that when the analysis was restricted to the mild HTN-ICH subgroup, the influence of SVD markers on functional dependence was limited. Thus, it would be better to pay more attention to age and admission NIHSS score to predict the recoveries of neurological function. Our study also suggested that lacunes and the specific imaging characteristics, rather than the overall severity of SVD burden, were responsible for the high risk of stroke recurrence in HTN-ICH patients. The pathophysiological mechanisms of lacunes were related to atherosclerosis and microenvironment of arterioles less than 100 µm. Moreover, further changes in the blood–brain barrier and cerebral blood flow might be the cause of recurrent stroke [33)] . Previous study has also reported that lacunes increased the risk of stroke recurrence in non-CAA-ICH patients, which is in agreement with our results [34)] . Our study has important clinical implications, which enable clinicians to better identify secondary prevention measures, especially in conscious and spontaneous ICH patients without surgical treatment, who might be easily ignored by doctors. Another strength of our work is the systematic evaluation and summary of different SVD scores by trained raters using validated scales. Our study also has some limitations. First, due to the rigidity of the inclusion criteria, the sample size in our study was small, and the findings need to be confirmed in future larger studies. Second, patients who could not be definitively diagnosed with CAA-ICH or HTN-ICH were excluded, which limited the strength of some of our results. Third, we did not assess the cognitive function during follow-up. Finally, our study was limited by the small number of some clinical outcomes, with only 8 patients had recurrent hemorrhagic strokes and 13 patients had recurrent ischemic strokes, rendering further analysis difficult. In future study, we would like to include more cases to separately explore the prediction value of different SVD scores on recurrent cerebral hemorrhage and recurrent cerebral infarction. The results may help clinicians to better determine the use of medications, such as anti-platelet drugs and statins. In conclusion, the CAA-SVD score and the total number of SVD markers might help doctors identify high-risk patients with poor prognosis in the mild CAA-ICH group. It would be better for neurologists to focus on lacunes rather than the overall burden of SVD markers to identify patients who might have recurrent strokes in the mild HTN-ICH group.

Funding Information

This work was sponsored by National Natural Science Foundation of China (81771281) and (81471177).

Compliance with Ethical Standards Conflicts of Interest

The authors declare no conflicts of interest.

Ethical Approval

This study was approved by the ethics committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Written informed consent to collect data and clinical outcomes was obtained from the patient or a legally authorized representative in all cases.
Table 3.

Univariate analysis of factors associated with stroke recurrences

CAA-related ICH ( n = 60) HTN-related ICH ( n = 103)
HR (95% CI) P value HR (95% CI) P value
Baseline clinical characteristics
Age0.964 (0.893-1.041)0.3521.032 (0.985-1.081)0.186
Male2.073 (0.495-8.677)0.3181.226 (0.401-3.748)0.721
Hypertension0.577 (0.138-2.413)0.451//
Diabetes mellitus1.861 (0.375-9.227)0.4470.632 (0.174-2.298)0.486
Dyslipidemia1.223 (0.142-7.537)0.6370.728 (0.331-1.601)0.429
Previous stroke0.494 (0.061-4.016)0.5101.700 (0.377-7.678)0.490
Antiplatelet use0.756 (0.222-4.078)0.5290.576 (0.067-5.387)0.689
Statin use1.275 (0.653-4.338)0.2640.835 (0.321-3.965)0.189
Admission NIHSS1.116 (0.960-1.297)0.1531.124 (0.986-1.280)0.081
Admission GCS0.749 (0.223-2.519)0.6410.728 (0.331-1.601)0.429
Hematoma volume1.033 (1.001-1.066)0.0451.012 (0.950-1.079)0.710
Imaging markers of CVSD
Lacunes2.120 (0.428-10.510)0.3576.132 (2.054-18.311)0.001
CMBs1.108 (0.892-1.376)0.3540.797 (0.258-2.455)0.692
EPVS0.771 (0.184-3.227)0.7221.957 (0.658-5.825)0.228
WMH1.376 (0.936-2.024)0.1051.251 (0.965-1.622)0.091
cSS1.979 (0.941-4.160)0.0722.176 (0.747-6.343)0.154
The original SVD score2.449 (1.076-5.575)0.0331.911 (1.193-3.061)0.007
The modified SVD score1.904 (1.051-3.448)0.0341.586 (1.047-2.403)0.030
The refined SVD score//1.589 (1.007-2.507)0.047
The CAA-SVD score1.894 (1.216-2.950)0.005//
Total number of SVD markers3.839 (1.505-9.794)0.0052.136 (1.218-3.745)0.008

Abbreviation: HTN = Hypertension; CAA = Cerebral Amyloid Angiopathy; ICH = Intracerebral Hemorrhage; NIHSS = National Institutes of Health Stroke Scale; GCS = Glasgow Coma Scale; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMHs = White Matter Hyperintensities; EPVSs = Enlarged Perivascular Spaces; CSO = Centrum Semiovale ; BG = Basal Ganglia; SVD = Small Vessel Disease.

Table 4.

Multivariable adjusted models exploring associations of individual SVD markers and different SVD scores and functional dependence * in CAA-related ICH patients

OR (95% CI) P value
Model 1: individual SVD markers
Age1.098 (0.983-1.226)0.097
Admission NIHSS1.211 (0.967-1.516)0.095
Hematoma volume0.985 (0.903-1.075)0.735
Lacunes0.349 (0.023-5.400)0.451
Lobar CMBs2.486 (0.360-17.156)0.355
Severe CSO-EPVS4.778 (0.568-400.125)0.150
WMH2.881 (0.234-35.407)0.408
cSS4.665 (1.388-15.679)0.013
Model 2: different total SVD scores
Age1.120 (1.014-1.237)0.026
Admission NIHSS1.249 (0.979-1.594)0.074
Hematoma volume1.023 (0.935-1.120)0.617
The original SVD score0.129 (0.010-1.640)0.114
The modified SVD score3.816 (0.321-45.355)0.289
The refined SVD score0.802 (0.095-6.764)0.839
The CAA-SVD score3.429 (1.518-7.748)0.003
Total number of SVD markers1.410 (0.180-11.030)0.744

Abbreviation: SVD = Small Vessel Disease; CAA = Cerebral amyloid angiopathy; NIHSS = National Institutes of Health Stroke Scale; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMH = White Matter Hyperintensities; EPVS = Enlarged Perivascular Spaces; CSO = Centrum Semiovale.

* Functional dependence was measured 3 months after onset and defined as the modified Rankin scale (mRS) >2

Table 5.

Multivariable adjusted models exploring associations of individual SVD markers and different SVD scores and functional dependence * in HTN-related ICH patients

OR (95% CI) P value
Model 1: individual SVD markers
Age1.095 (1.015-1.181)0.019
Admission NIHSS1.679 (1.316-2.142)<0.001
Admission GCS0.596 (0.150-2.374)0.463
Hematoma volume0.977 (0.873-1.093)0.685
Lacunes0.233 (0.025-1.969)0.177
Deep CMBs3.195 (0.920-11.101)0.068
Severe BG-EPVS0.634 (0.050-8.026)0.725
WMH1.493 (0.514-4.336)0.461
cSS3.672 (0.478-28.229)0.211
Model 2: different total SVD scores
Age1.066 (0.998-1.138)0.057
Admission NIHSS1.556 (1.262-1.918)<0.001
Admission GCS0.941 (0.277-3.194)0.922
Hematoma volume0.950 (0.856-1.055)0.337
The original SVD score0.459 (0.102-2.058)0.309
The modified SVD score1.514 (0.913-2.512)0.108
The refined SVD score1.185 (0.184-7.624)0.858
The CAA-SVD score1.439 (0.277-7.475)0.665
Total number of SVD markers0.724 (0.213-2.460)0.605

Abbreviation: SVD = Small Vessel Disease; HTN = Hypertension; NIHSS = National Institutes of Health Stroke Scale; GCS = Glasgow Coma Scale; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMH = White Matter Hyperintensities; EPVS = Enlarged Perivascular Spaces; BG = Basal Ganglia.

* Functional dependence was measured 3 months after onset and defined as the modified Rankin scale (mRS) >2

Table 6.

Multivariable adjusted models exploring associations of individual SVD markers and different total SVD scores and stroke recurrences in CAA-related ICH patients

HR (95% CI) P value
Model 1: individual SVD markers
Age0.948 (0.868-1.036)0.241
Hematoma volume1.022 (0.983-1.062)0.266
Lacunes2.211 (0.257-19.055)0.470
Lobar CMBs1.013 (0.177-5.804)0.988
Severe CSO-EPVS1.596 (0.348-7.328)0.548
WMH1.376 (0.936-2.024)0.105
cSS1.953 (0.929-4.107)0.078
Model 2: different total SVD scores
Age0.945 (0.874-1.020)0.148
Hematoma volume1.020 (0.977-1.065)0.370
The original SVD score1.107 (0.094-12.998)0.935
The modified SVD score0.549 (0.049-6.218)0.629
The refined SVD score3.468 (0.447-26.881)0.234
The CAA-SVD score1.304 (0.548-3.101)0.549
Total number of SVD markers3.765 (1.467-9.663)0.006

Abbreviation: SVD = Small Vessel Disease; CAA = Cerebral amyloid angiopathy; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMH = White Matter Hyperintensities; EPVS = Enlarged Perivascular Spaces; CSO = Centrum Semiovale.

Table 7.

Multivariable adjusted models exploring associations of individual SVD markers and different total SVD scores and stroke recurrences in HTN-related ICH patients

HR (95% CI) P value
Model 1: individual SVD markers
Age1.032 (0.985-1.081)0.186
Admission NIHSS1.108 (0.954-1.288)0.179
Lacunes5.064 (1.697-15.116)0.004
Deep CMBs0.572 (0.150-2.174)0.412
Severe BG-EPVS0.275 (0.020-3.857)0.338
WMH1.330 (0.606-2.916)0.477
cSS3.135 (0.799-12.309)0.101
Model 2: different total SVD scores
Age1.035 (0.980-1.093)0.212
Admission NIHSS1.111 (0.968-1.276)0.135
The original SVD score1.833 (0.702-4.784)0.216
The modified SVD score0.575 (0.119-2.792)0.493
The refined SVD score1.056 (0.264-4.232)0.939
The CAA-SVD score1.582 (0.614-4.074)0.342
Total number of SVD markers2.136 (1.218-3.745)0.008

Abbreviation: SVD = Small Vessel Disease; HTN = Hypertension; NIHSS = National Institutes of Health Stroke Scale; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMH = White Matter Hyperintensities; EPVS = Enlarged Perivascular Spaces; BG = Basal Ganglia.

  31 in total

1.  White Matter Hyperintensity-Adjusted Critical Infarct Thresholds to Predict a Favorable 90-Day Outcome.

Authors:  Jatinder Patti; Johanna Helenius; Ajit S Puri; Nils Henninger
Journal:  Stroke       Date:  2016-09-15       Impact factor: 7.914

2.  Hemorrhage recurrence risk factors in cerebral amyloid angiopathy: Comparative analysis of the overall small vessel disease severity score versus individual neuroimaging markers.

Authors:  Gregoire Boulouis; Andreas Charidimou; Marco Pasi; Duangnapa Roongpiboonsopit; Li Xiong; Eitan Auriel; Ellis S van Etten; Sergi Martinez-Ramirez; Alison Ayres; Anastasia Vashkevich; Kristin M Schwab; Jonathan Rosand; Joshua N Goldstein; M Edip Gurol; Steven M Greenberg; Anand Viswanathan
Journal:  J Neurol Sci       Date:  2017-07-09       Impact factor: 3.181

3.  Prevalence and mechanisms of cortical superficial siderosis in cerebral amyloid angiopathy.

Authors:  Andreas Charidimou; Rolf Hans Jäger; Zoe Fox; Andre Peeters; Yves Vandermeeren; Patrice Laloux; Jean-Claude Baron; David John Werring
Journal:  Neurology       Date:  2013-07-17       Impact factor: 9.910

4.  MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging.

Authors:  F Fazekas; J B Chawluk; A Alavi; H I Hurtig; R A Zimmerman
Journal:  AJR Am J Roentgenol       Date:  1987-08       Impact factor: 3.959

5.  Cerebral small vessel disease burden and functional and radiographic outcomes in intracerebral hemorrhage.

Authors:  Vasileios-Arsenios Lioutas; Bo Wu; Casey Norton; Johanna Helenius; Janhavi Modak; Magdy Selim
Journal:  J Neurol       Date:  2018-09-21       Impact factor: 4.849

6.  Advancing diagnostic criteria for sporadic cerebral amyloid angiopathy: Study protocol for a multicenter MRI-pathology validation of Boston criteria v2.0.

Authors:  Andreas Charidimou; Matthew P Frosch; Rustam Al-Shahi Salman; Jean-Claude Baron; Charlotte Cordonnier; Mar Hernandez-Guillamon; Jennifer Linn; Nicolas Raposo; Mark Rodrigues; Jose Rafael Romero; Julie A Schneider; Stefanie Schreiber; Eric E Smith; Mark A van Buchem; Anand Viswanathan; Frank A Wollenweber; David J Werring; Steven M Greenberg
Journal:  Int J Stroke       Date:  2019-09-12       Impact factor: 5.266

7.  Cortical superficial siderosis predicts early recurrent lobar hemorrhage.

Authors:  Duangnapa Roongpiboonsopit; Andreas Charidimou; Christopher M William; Arne Lauer; Guido J Falcone; Sergi Martinez-Ramirez; Alessandro Biffi; Alison Ayres; Anastasia Vashkevich; Oluwole O Awosika; Jonathan Rosand; M Edip Gurol; Scott B Silverman; Steven M Greenberg; Anand Viswanathan
Journal:  Neurology       Date:  2016-09-30       Impact factor: 9.910

8.  Cortical superficial siderosis multifocality in cerebral amyloid angiopathy: A prospective study.

Authors:  Andreas Charidimou; Gregoire Boulouis; Duangnapa Roongpiboonsopit; Eitan Auriel; Marco Pasi; Kellen Haley; Ellis S van Etten; Sergi Martinez-Ramirez; Alison Ayres; Anastasia Vashkevich; Kristin M Schwab; Joshua N Goldstein; Jonathan Rosand; Anand Viswanathan; Steven M Greenberg; M Edip Gurol
Journal:  Neurology       Date:  2017-10-25       Impact factor: 11.800

9.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.

Authors:  Joanna M Wardlaw; Eric E Smith; Geert J Biessels; Charlotte Cordonnier; Franz Fazekas; Richard Frayne; Richard I Lindley; John T O'Brien; Frederik Barkhof; Oscar R Benavente; Sandra E Black; Carol Brayne; Monique Breteler; Hugues Chabriat; Charles Decarli; Frank-Erik de Leeuw; Fergus Doubal; Marco Duering; Nick C Fox; Steven Greenberg; Vladimir Hachinski; Ingo Kilimann; Vincent Mok; Robert van Oostenbrugge; Leonardo Pantoni; Oliver Speck; Blossom C M Stephan; Stefan Teipel; Anand Viswanathan; David Werring; Christopher Chen; Colin Smith; Mark van Buchem; Bo Norrving; Philip B Gorelick; Martin Dichgans
Journal:  Lancet Neurol       Date:  2013-08       Impact factor: 44.182

10.  New Silent Cerebral Infarction in Patients with Acute Non-Cerebral Amyloid Angiopathy Intracerebral Hemorrhage as a Predictor of Recurrent Cerebrovascular Events.

Authors:  Yuan-Wei Wang; Guo-Ming Zhang
Journal:  Med Sci Monit       Date:  2019-01-14
View more
  1 in total

1.  Higher Burden of Cerebral Small Vascular Disease Predicts Major Adverse Cardiac and Cerebrovascular Events and Is Related to Abnormal Blood Pressure Variability Pattern in Hypertension Patients.

Authors:  Xiaomeng Xu; Shu Huang; YuE Zeng; Yulan Feng; Dongqi Yue; Fanxia Shen; Yang Gao; Bei Zhang; Yang Yang; Lin Gu; Yi Fu
Journal:  Front Aging Neurosci       Date:  2022-03-08       Impact factor: 5.750

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.